Not yet recruitingNCT06123624Updated Nov 9, 2023

Desflurane and Sevoflurane on Remifentanil Requirement

An interventional study of Desflurane Inhalation Solution and Sevoflurane Inhalation Solution in Spinal Diseases, sponsored by Ajou University School of Medicine. Not yet recruiting. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by Ajou University School of Medicine · Not applicable, Interventional, and Prevention

From the registry’s dates

Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as not yet recruiting.

Phase: Not applicable
Study type: Interventional
Enrollment: 78
Allocation: Randomized
Ages: 19 Years to 80 Years
Sex: All

Study summary

The primary purpose of this study is to compare the desflurane and sevoflurane on remifentanil requirement using analgesia nociception index-guided anesthesia in patients undergoing spine surgery.

Conditions studied

Spinal Diseases

Browse trials for

Spinal Diseases 174

In context

Spinal Diseases

174 studies on the registry are indexed under Spinal Diseases; 39 are open to participants now.

This study's planned enrollment of 78 is above the median of 60 across 106 interventional studies indexed under Spinal Diseases.

Browse Spinal Diseases studies →

Lead sponsor

Ajou University School of Medicine is the lead sponsor of 173 studies on the registry; 16 are open to participants now.

Browse Ajou University School of Medicine studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 19 Years to 80 Years
Sexes eligible: All
Accepts healthy volunteers: No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Clinical diagnosis of herniated disc, injury of spinal cord, and neoplasm of spinal meninges

Exclusion criteria

Exclusion Criteria:

Hyperbilirubinemia
Prior chronic pain
Prior opioid abuse
Cardiac arrythmia

Study design

Phase: Not applicable
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 78 participants (estimated)

Study arms

Experimental
Desflurane group
Drug: Desflurane Inhalation Solution
Placebo comparator
Sevoflurane group
Drug: Sevoflurane Inhalation Solution

Interventions

DrugDesflurane Inhalation Solution
Keeping the anesthesia using desflurane inhalation solution as 1 minimal alveolar concentration
DrugSevoflurane Inhalation Solution
Keeping the anesthesia using sevoflurane inhalation solution as 1 minimal alveolar concentration

What researchers measure

Primary outcomes

remifentanil requirement
assessing the total dose of remifentanil administered from skin incision until skin suture
Time frame: at time of the end of skin suture (up to 3 hours)

Study locations

No study locations are listed for this record.

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Aug 2024, 9 months later.

Of 40 non-industry interventional studies with no phase under Spinal Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 9 months is below that.

Counting every sponsor, half of 43 studies reached it within 26 months; a quarter within 16 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered: Nov 1, 2023
First posted: Nov 9, 2023
StartEst.: Nov 27, 2023
Primary completionEst.: Aug 30, 2024
CompletionEst.: Aug 30, 2024
Last update: Nov 9, 2023

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT06123624
Lead sponsor: Ajou University School of Medicine
Responsible party: Ji Eun Kim (Assistant professor, Ajou University School of Medicine) — Principal investigator
First posted: Nov 9, 2023
Start date: Nov 27, 2023 (estimated)
Primary completion: Aug 30, 2024 (estimated)
Completion: Aug 30, 2024 (estimated)
Last update: Nov 9, 2023

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Spinal Diseases →

Other studies from this sponsor

Ajou University School of Medicine →

Start the discussion